Mithra Pharmaceuticals SA (0R91.L)

6,41 -0,09 (-1,31%) Al cierre: 06:18PM BST

Mithra Pharmaceuticals SA

Rue Saint-Georges 5
Liège 4000
Belgium
32 4 349 28 22
https://www.mithra.com

Sector(es): 
Sector: 
Empleados a tiempo completo: 

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Christophe Marechal	Co-CEO & CFO	N/A	N/A	N/A
Mr. Xavier Paoli M.Sc.	COO & Co-CEO	N/A	N/A	N/A
Dr. Graham K. Dixon Ph.D.	Chief Scientific Officer	N/A	N/A	1961
Mr. Alex Sokolowski	Head of Investor Relations	N/A	N/A	N/A
Fanny Rozenberg	Secretary of the Board & General Counsel	N/A	N/A	N/A
Fanny Storms	Compliance Officer	N/A	N/A	N/A
Mr. Frederique Depraetere	Communication Director	N/A	N/A	N/A
Ms. Catherine Lejeune	HR Director	N/A	N/A	N/A
Mr. Jean-Manuel Fontaine	Chief Commercial & External Affairs Officer	N/A	N/A	N/A
Prof. Jean-Michel Foidart M.D., Ph.D.	President of the Scientific Advisory Board & Executive Director	7,12k	N/A	N/A

Los importes son a partir de 31 de diciembre de 2016 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.

Gobierno corporativo

El ISS Governance QualityScore de Mithra Pharmaceuticals SA, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.